Dr. Metzger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3800
Education & Training
- Universite Libre de BruxelesPhD, Breast Cancer, 2009 - 2013
- Federal University of Minas GeraisClass of 2003
Certifications & Licensure
- MA State Medical License 2013 - 2025
Awards, Honors, & Recognition
- Clinical Scholar Award San Antonio Breast Cancer Symposium, 2010
Clinical Trials
- Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) Start of enrollment: 2016 May 24
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Start of enrollment: 2017 Jun 21
- Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen Start of enrollment: 2007 Dec 15
Publications & Presentations
PubMed
- 1 citationsImplementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium.Maria Alice Franzoi, Arlindo R Ferreira, Antoine Lemaire, Joseph Rodriguez, Jessica Grosjean
The Lancet Regional Health. Europe. 2024-09-01 - 1 citationsInternational survey on invasive lobular breast cancer identifies priority research questions.Steffi Oesterreich, Leigh Pate, Adrian V Lee, Fangyuan Chen, Rachel C Jankowitz
NPJ Breast Cancer. 2024-07-20 - 1 citationsQualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Ziming Du, Yu-An Chen
NPJ Breast Cancer. 2024-01-02
Journal Articles
- Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first line trastuzu...Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU, Clin Breast Cancer, 8/1/2013
- The magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA trialMetzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R..., J Clin Oncol, 6/1/2013
- Analysis of Regional Timelines to Set up a Global Phase III Clinical Trial in Breast Cancer: The ALTTO ExperienceMetzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu ..., Oncologist, 1/1/2013
- Join now to see all
Lectures
- HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.2019 ASCO Annual Meeting - 6/1/2019
- Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
- Surgery May Be Unnecessary for Common Precancerous Breast ConditionDecember 14th, 2024
- Phase III PATINA Study Shows Hope for HR+, HER2+ CancerDecember 13th, 2024
- CDK 4/6 Inhibitor Boosts HR+, HER2+ Breast Cancer CareDecember 12th, 2024
- Join now to see all
Professional Memberships
- Member
Other Languages
- Portuguese, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: